1-18 of 18
Peter Mueller
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial

Free
Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, Eva-Maria Wagner, Lutz Peter Mueller, Schmid Christoph, Stefan W. Krause, Wolfgang Bethge, Edgar Jost, Uwe Platzbecker, Stefan Klein, Jörg Schubert, Judith Niederland, Martin Kaufmann, Kerstin Schäfer-Eckart, Markus Schaich, Henning Baldauf, Friedrich Stölzel, Cathleen Petzold, Christoph Röllig, Nael Alakel, Björn Steffen, Beate Hauptrock, Christian Reicherts, Christoph Schliemann, Hubert Serve, Alexander H. Schmidt, Martin Bornhäuser, Jan-Henrik Mikesch, Johannes Schetelig
Journal: Blood
Blood (2022) 140 (Supplement 1): 9–11.
https://doi.org/10.1182/blood-2022-159962
Published: 2022
Journal Articles

Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All- Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)

Free
Inga Hund, Maria Hess, Julia Stomper, Gabriele Greve, Jan Mitschke, Christoph Niemöller, Tobias Ma, David Uhl, Felicitas R. Thol, Michael Heuser, Gesine Bug, Martina Crysandt, Lutz Peter Mueller, Andreas Neubauer, Justus Duyster, Hartmut Dohner, Melanie Boerries, Heiko Becker, Michael Luebbert
Journal: Blood
Blood (2022) 140 (Supplement 1): 3383–3384.
https://doi.org/10.1182/blood-2022-163220
Published: 2022
Journal Articles

Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Free
Sonia Jaramillo Segura, Maxi Wass, Judith Schaffrath, Kathrin Rieger, Axel Nogai, Mathias Haenel, Regina Herbst, Friedrich Stoelzel, Christoph Röllig, Edgar Jost, Richard F. Schlenk, Richard Noppeney, Christian H. Brandts, Utz Krug, Katharina S. Goetze, Sebastian Buske, Axel Florschütz, Jörg Schubert, Bernhard Opitz, Martin Mohren, Eva Eßeling, Stephan von Witzendorff, Marion Subklewe, Martin Kaufmann, Norbert Frickhofen, Christian W Scholz, Kerstin Schäfer-Eckart, Volker Kunzmann, Martin Schmidt-Hieber, Herbert G. Sayer, Andreas Rank, Philipp Hemmati, Frank Schueler, Simone Kowoll, Marina Scheller, Jörg Steighardt, Bayram Edemir, Lutz Peter Mueller, Irit Gliko-Kabir, Beatrice Ludwig-Kraus, Sabine Edemir, Ella Sorani, Mascha Binder, Abi Vainstein, Shaul Kadosh, Cora Gromann, Andreas Wienke, Claudia D. Baldus, Uwe Platzbecker, Hubert Serve, Martin Bornhaeuser, Christian Junghanss, Carsten Mueller-Tidow
Journal: Blood
Blood (2022) 140 (Supplement 1): 3338–3340.
https://doi.org/10.1182/blood-2022-166748
Published: 2022
Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-

Free
Martin Bornhaeuser, Christoph Schliemann, Johannes Schetelig, Christoph Rollig, Michael Kramer, Bertram Glass, Uwe Platzbecker, Andreas Burchert, Mathias Haenel, Lutz Peter Mueller, Stefan Klein, Gesine Bug, Dietrich W. Beelen, Wolf Roesler, Kerstin Schaefer-Eckart, Christoph Schmid, Edgar Jost, Georg Lenz, Johanna Tischer, Karsten Spiekermann, Markus Pfirrmann, Hubert Serve, Friedrich Stoelzel, Nael Alakel, Gerhard Ehninger, Wolfgang E. Berdel, Matthias Stelljes
Journal: Blood
Blood (2021) 138 (Supplement 1): 173.
https://doi.org/10.1182/blood-2021-145167
Published: 2021
Journal Articles

Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation with Venetoclax, Hypomethylating Agents and DLI - a Retrospective Multi Center Study

Free
Esther Schuler, MD, Eva-Maria Wagner-Drouet, MD, Salem Ajib, MD, Gesine Bug, Martina Crysandt, MD, Sabine Dressler, MD, Andreas Hausmann, MD, Daniela Heidenreich, MD, Klaus Hirschbühl, MD, Matthias Hoepting, MD, Edgar Jost, MD, Jennifer Kaivers, MD, Stefan A Klein, MD, Lambros Kordelas, MD, Oliver Kriege, MD, Lutz Peter Mueller, MD, Christina Rautenberg, MD, Judith Schaffrath, MD, Christoph Schmid, MD, Daniel Wolff, MD, Martin Bornhaeuser, MD, Thomas Schroeder, MD, Guido Kobbe, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4563.
https://doi.org/10.1182/blood-2019-125087
Published: 2019
Journal Articles

Assessment of Residual Bulky Tumor Using FDG-PET In Patients with Advanced-Stage Hodgkin Lymphoma After Completion of Chemotherapy: Final Report of the GHSG HD15 Trial

Free
Andreas Engert, MD, Carsten Kobe, Jana Markova, Heinz Haverkamp, Peter Borchmann, Felicitas Hitz, Josee Zijlstra, Hans Eich, Rolf-Peter Mueller, Markus Dietlein, Volker Diehl
Journal: Blood
Blood (2010) 116 (21): 764.
https://doi.org/10.1182/blood.V116.21.764.764
Published: 2010
Journal Articles

Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial

Free
Andreas Engert, MD, Peter Borchmann, MD, Annette Pluetschow, Bastian von Tresckow, Jana Markova, Felicitas Hitz, Zdenek Kral, Richard Greil, MD, Max S Topp, Matthias Villalobos, Josee M. Zijlstra, Martin Soekler, Harald Stein, MD, Hans-Theodor Eich, Rolf-Peter Mueller, Michael Fuchs, Volker Diehl
Journal: Blood
Blood (2010) 116 (21): 765.
https://doi.org/10.1182/blood.V116.21.765.765
Published: 2010
Journal Articles

Two Cycles of ABVD Followed by Involved Field Radiotherapy with 20 Gray (Gy) Is the New Standard of Care in the Treatment of Patients with Early-Stage Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group (GHSG) HD10. Study Supported by the Deutsche Krebshilfe and in Part by the Competence Network Malignant Lymphoma.

Free
Andreas Engert, MD, Volker Diehl, MD, Emeritus, Annette Pluetschow, Hans T. Eich, Richard Herrmann, MD, Bernd Doerken, Lothar Kanz, MD, Richard Greil, Jana Markova, Michael Fuchs, Peter Borchmann, PD, Dr., Hans Konrad Mueller-Hermelink, Rolf Peter Mueller
Journal: Blood
Blood (2009) 114 (22): 716.
https://doi.org/10.1182/blood.V114.22.716.716
Published: 2009
Journal Articles

Combined Modality Treatment with Intensified Chemotherapy and Dose-Reduced Involved Field Radiotherapy in Patients with Early Unfavourable Hodgkin Lymphoma (HL): Final Analysis of the German Hodgkin Study Group (GHSG) HD11 Trial.

Free
Peter Borchmann, Volker Diehl, Helen Goergen, Horst Mueller, Rolf Peter Mueller, Hans T. Eich, Hans Konrad Mueller-Hermelink, Richard Herrmann, MD, Jana Markova, Anthony D. Ho, MD, PhD, Wolfgang Hiddemann, Bernd Doerken, Richard Greil, Andreas Engert, MD
Journal: Blood
Blood (2009) 114 (22): 717.
https://doi.org/10.1182/blood.V114.22.717.717
Published: 2009
Journal Articles

Hodgkin Lymphoma in Adolescents Treated with Adult Protocols: An Analysis From the German Hodgkin Study Group (GHSG).

Free
Dennis A. Eichenauer, Henning Bredenfeld, Jeremy Franklin, Heinz Haverkamp, Horst Mueller, Hans T. Eich, Rolf-Peter Mueller, Michael Fuchs, Peter Borchmann, Volker Diehl, Andreas Engert
Journal: Blood
Blood (2009) 114 (22): 719.
https://doi.org/10.1182/blood.V114.22.719.719
Published: 2009
Journal Articles

Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated Followed by 4 Cycles of BEACOPP Baseline with Our without Radiotherapy in Patients in Advanced Stage Hodgkin Lymphoma (HL): Final Analysis of the Randomised HD12 Trial of the German Hodgkin Study Group (GHSG).

Free
Volker Diehl, Heinz Haverkamp, Rolf Peter Mueller, Hans Theodor Eich, Hans Konrad Mueller-Hermelink, Thomas Cerny, Jana Markova, Anthony Ho, Lothar Kanz, Richard Greil, Wolfgang Hiddemann, Andreas Engert
Journal: Blood
Blood (2008) 112 (11): 1558.
https://doi.org/10.1182/blood.V112.11.1558.1558
Published: 2008
Journal Articles

Dose-Intensified Combined Modality Treatment with 2 Cycles of BEACOPP Escalated Followed by 2 Cycles of ABVD and Involved Field Radiotherapy (IF-RT) Is Superior to 4 Cycles of ABVD and IFRT in Patients with Early Unfavourable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial

Free
Peter Borchmann, Andreas Engert, Annette Pluetschow, Michael Fuchs, Jana Markova, Andreas Lohri, Zdenek Kral, Richard Greil, Max Topp, Matthias Villalobos, Jose Zijlstra, MD, Martin Soekler, Harald Stein, Hans Theodor Eich, Rolf Peter Mueller, Volker Diehl
Journal: Blood
Blood (2008) 112 (11): 367.
https://doi.org/10.1182/blood.V112.11.367.367
Published: 2008
Journal Articles

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

Free
Clinical Trials & Observations
Carsten Kobe, Markus Dietlein, Jeremy Franklin, Jana Markova, Andreas Lohri, Holger Amthauer, Susanne Klutmann, Wolfram H. Knapp, Josee M. Zijlstra, Andreas Bockisch, Matthias Weckesser, Reinhard Lorenz, Mathias Schreckenberger, Roland Bares, Hans T. Eich, Rolf-Peter Mueller, Michael Fuchs, Peter Borchmann, Harald Schicha, Volker Diehl, Andreas Engert
Journal: Blood
Blood (2008) 112 (10): 3989–3994.
https://doi.org/10.1182/blood-2008-06-155820
Published: 2008
Journal Articles

Marked Improvement of Skin Involvement in Severe Progressive Systemic Sclerosis after Transplantation of Mesenchymal Stem Cells from an Allogeneic Haploidentical Related Donor.

Free
Maximilian Christopeit, MD, Marit Schendel, MD, Lutz Peter Mueller, MD, Gernot Keyszer, MD, Gerhard Behre, MD
Journal: Blood
Blood (2007) 110 (11): 4865.
https://doi.org/10.1182/blood.V110.11.4865.4865
Published: 2007
Journal Articles

HD12 Randomised Trial Comparing 8 Dose-Escalated Cycles of BEACOPP with 4 Escalated and 4 Baseline Cycles in Patients with Advanced Stage Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Lymphoma Study Group (GHSG), University of Cologne, D-50924 Cologne, Germany.

Free
Andreas Engert, Jeremy Franklin, Rolf-Peter Mueller, Hans-Theodor Eich, Axel Gossmann, Hans Konrad Mueller-Hermelink, Thomas Cerny, Jana Markova, Anthony D. Ho, Lothar Kanz, Richard Greil, Wolfgang Hiddemann, Beate Pfistner, Volker Diehl
Journal: Blood
Blood (2006) 108 (11): 99.
https://doi.org/10.1182/blood.V108.11.99.99
Published: 2006
Journal Articles

Recent Interim Analysis of the HD11 Trial of the GHSG: Intensification of Chemotherapy and Reduction of Radiation Dose in Early Unfavorable Stage Hodgkin’s Lymphoma.

Free
Volker Diehl, Corinne Brillant, Andreas Engert, Ralf-Peter Mueller, Hans-Theodor Eich, Konrad Mueller-Hermelink, Richard Herrmann, Jana Markova, Anthony Ho, Wolfgang Hiddemann, Bernd Doerken, Richard Greil, Andreas Josting, Beate Pfistner
Journal: Blood
Blood (2005) 106 (11): 816.
https://doi.org/10.1182/blood.V106.11.816.816
Published: 2005
Journal Articles

Single High-Dose Chemoradiotherapy Versus Tandem High Dose Melphalan Followed by Auto-SCT for Advanced Multiple Myeloma. Preliminary Analysissis.

Free
Hermann Einsele, MD, Peter Liebisch, MD, Ralf Bargou, MD, Christoph Meisner, Bernd Metzner, MD, Hannes Wandt, MD, Hans-Heinrich Wolf, MD, Orhan Sezer, MD, Jochen Casper, MD, Michael Pfreundschuh, MD, Georg Maschmeyer, MD, Christian Straka, MD, Lothar Truemper, MD, Nikolaus Kroeger, MD, Peter Mueller, MD, Bernd Hertenstein, MD, Nikolaus Frickhofen, MD, Paolo Coser, MD, Michael Bamberg, MD, Holger Hebart, MD, Lothar Kanz, MD
Journal: Blood
Blood (2004) 104 (11): 537.
https://doi.org/10.1182/blood.V104.11.537.537
Published: 2004
Journal Articles

Superagonistic Anti-CD28 Antibody TGN1412 as a Potential Immunotherapeutic for the Treatment of B Cell Chronic Lymphocytic Leukemia.

Free
Chia-Huey Lin, PhD, Thomas Kerkau, MD, Christine Guntermann, PhD, Martin Trischler, PhD, Niklas Beyersdorf, MD, Yvonne Scheuring, Hans-Peter Tony, MD, Christian Kneitz, MD, Martin Wilhelm, MD, Peter Mueller, PhD, Thomas Huenig, PhD, Thomas Hanke, PhD
Journal: Blood
Blood (2004) 104 (11): 2519.
https://doi.org/10.1182/blood.V104.11.2519.2519
Published: 2004